Ipsen 5i is a novel potent pharmacoperone for intracellularly retained melanocortin-4 receptor mutants

Ya-Xiong Tao*† and Hui Huang†
Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA

INTRODUCTION
The melanocortin-4 receptor (MC4R) is a G protein-coupled receptor (GPCR) that is widely expressed in the central nervous system including the cortex, thalamus, hypothalamus, hippocampus, brainstem, and spinal cord (1, 2). The MC4R plays a vital role in the leptin-melanocortin pathway in regulating energy homeostasis, affecting both energy intake and expenditure (3, 4). Tissue-specific knockout studies revealed that the MC4R expressed in the paraventricular nucleus and/or amygdala neurons regulates food intake (5) whereas the MC4R expressed in the cholinergic neurons of the prefrontal cortex, caudate-putamen, brainstem, and spinal cord (1, 2). The MC4R plays a vital role in the energy homeostasis, affecting both energy intake and expenditure (3, 4). Inactivating mutations of the MC4R mutants are misfolded and trapped intracellularly by the stringent endoplasmic reticulum (ER) quality control system (11–13). These mutant MC4Rs may only have minor folding defect but retain pharmacological function. If they are escorted onto the cell surface, they can potentially bind the ligand and initiate signaling. Several studies have attempted to promote the anterograde trafficking of these mutant MC4R, using molecular chaperone (14), chemical chaperone (15), or pharmacological chaperone (or pharmacoperone) (13, 16–18).

The therapeutic potential of molecular and chemical chaperones is limited due to disruption of proteostasis or significant side effects whereas pharmacoperone is a promising approach. It has been tested in numerous human diseases caused by misfolded proteins, including neurodegenerative diseases, cystic fibrosis, lysosomal storage diseases, and cancer, with several promising clinical trials underway [reviewed in Ref. (19–21)]. Misfolding is also the most common defect in diseases caused by mutations in GPCR genes (22). Pharmacoperones have also been identified for several GPCRs, including rhodopsin, V2 arginine vasopressin receptor, gonadotropin-releasing hormone receptor, calcium-sensing receptor, and others [reviewed in Ref. (21)]. In the MC4R, we and others reported a few molecules that act as pharmacoperones (13, 16–18). These compounds have low affinities for the MC4R, therefore, usually need high concentrations (10^-6 M and higher) to achieve any rescue.

Ipsen 5i was synthesized and identified as a high-affinity antagonist and partial inverse agonist of MC4R competing with [Nle 4,D-Phe 7]-α-melanocyte stimulating hormone (NDP-MSH) for binding to the MC4R (23–25). We reported recently that although it decreases basal signaling at the classical Gs-cAMP pathway, it acts as an agonist in the mitogen-activated protein kinase pathway (26). In this study, we investigated whether Ipsen 5i could...
Tao and Huang

Ipsen 5i as a novel MC4R pharmacoperone

act as a pharmacoperone promoting the proper folding and trafficking of intracellularly retained mutant MC4Rs using multiple cell lines. A total of 15 mutants were studied, including 11 (S58C, N62S, I69R, P78L, C84R, G98R, Y157S, W174C, P260Q, F261S, and C271Y) that are retained intracellularly and four (∆88-92, D90N, I102S, and N274S) that are expressed relatively normally at the cell surface with other or no defects.

**MATERIALS AND METHODS**

**MATERIALS AND PLASMIDS**

NDP-MSH was purchased from Peptides International (Louisville, KY), α-MSH from Pi Proteomics (Huntsville, AL, USA), SHU9119 from Tocris Bioscience (Ellisville, MO, USA), and naltrexone hydrochloride from Alfa Aesar (Ward Hill, MA, USA). Ipsen 5i was custom synthesized by Enzo Life Science (Plymouth Meeting, PA, USA).[^125] I-cAMP was iodinated with chloramine T method (25). Wild type (WT) and mutant human MC4R with N-terminal c-myc tag and human melanocortin-3 receptor (MC3R) with N-terminal 3 × HA tag were previously constructed and sequenced (16, 27–30).

**CELL CULTURE AND TRANSFECTION**

Human embryonic kidney (HEK) 293, Neuro2a, and N1E-115 cells were purchased from American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum (HEK293 cells) or 10% fetal bovine serum (Neuro2a and N1E-115 cells) at 37°C. HEK293 cells were stably transfected using calcium phosphate precipitation method for transfection and 0.2 mg/ml G418 for selection. Neuro2a and N1E-115 cells were transiently transfected using jetPRIME transfection reagent (Polyplus-transfection, New York, NY, USA) and approximately 24 h later were used for ligand treatment. Cells were treated with indicated concentrations of ligands or 0.1% dimethyl sulfoxide (DMSO) as control for 24 h at 37°C. All cell culture plates were pretreated with 0.1% gelatin before cell plating unless noted otherwise.

**CONFOCAL MICROSCOPY**

HEK293 stable cells seeded into poly-ν-lysine-coated 8-well slides (Biocoat Cellware from Falcon, B&D Systems, Franklin Lakes, NJ, USA) were treated with 0.1% DMSO or 10^{-6} M Ipsen 5i for 24 h. On the day of experiment, cells were washed with phosphate buffered saline for immunohistochemistry (PBS-IH, 137 mM NaCl, 2.7 mM KCl, 1.4 mM KH₂PO₄, 4.3 mM Na₂HPO₄, pH 7.4) and fixed with 4% paraformaldehyde for 15 min. After blocking with 5% bovine serum albumin (BSA) in PBS-IH for 1 h, cells were incubated with mouse anti-myc 9E10 monoclonal antibody (Developmental Studies Hybridoma Bank, The University of Iowa, Iowa City, IA, USA) 1:40 diluted in PBS-IH containing 0.5% BSA for 1 h. Cells were then washed and incubated with Alexa Fluor 488-labeled goat anti-mouse antibody (Invitrogen, Grand Island, NY, USA) 1:2000 diluted in PBS-IH containing 0.5% BSA for 1 h. Cells were washed, covered with Vectashield mounting media (Vector Laboratories, Burlingame, CA, USA) and a glass coverslip, and dried overnight at 4°C. Images were taken using a Nikon A1 confocal microscope. All the steps were performed at room temperature unless mentioned otherwise.

**FLOW CYTOMETRY**

HEK293 stable cells and Neuro2a transiently transfected cells were treated with either 0.1% DMSO or Ipsen 5i (10^{-6} or 10^{-5} M) for 24 h at 37°C. On the day of experiment, cells were washed with ice-cold PBS-IH, detached, and precipitated by centrifugation at 500 × g for 5 min. Cells were then incubated with antibodies the same way as described above for confocal microscopy.

**FIGURE 1**

Schematic representation of MC4R. Naturally occurring mutations of the MC4R characterized in this study are highlighted; mutations that result in intracellular retention of the MC4R are highlighted in gray whereas mutations that do not interfere with the cell surface expression of the MC4R are highlighted in dark.
For immunostaining of MC3R, cells were incubated with HA.11 antibody (Covance, Princeton, NJ, USA) at 1:100 dilutions and then stained with secondary antibody as described above. Cells were analyzed using a C6 Accuri Cytometer (Accuri Cytometers, Ann Arbor, MI, USA). Fluorescence of cells expressing the DMSO-treated empty vector (pcDNA3.1) was used for background staining. The expression of the mutants was calculated as percentage of DMSO-treated WT receptor expression using the following formula: \[ \frac{(\text{mutant} - \text{pcDNA3.1})}{(\text{WT} - \text{pcDNA3.1})} \times 100\% \] (31).

**INTRACELLULAR cAMP ACCUMULATION ASSAY**

HEK293 stable cells and Neuro2A and N1E-115 transiently transfected cells were treated with 0.1% DMSO or different concentrations of Ipsen 5i for 24 h at 37°C. On the day of experiment, cells were washed twice with warm Waymouth’s MB752/1 media (Sigma-Aldrich, St. Louis, MO, USA) containing 1 mg/ml BSA (Waymouth’s/BSA) and incubated with Waymouth’s/BSA containing 0.5 mM isobutylmethylxanthine (Sigma-Aldrich) for 15 min. Cells were then stimulated with \(10^{-6}\)M NDP-MSH for 1 h at 37°C. Intracellular cAMP was extracted by adding 0.5 M perchloric acid containing 180 µg/ml theophylline (Sigma-Aldrich) and neutralized with 0.72 M KOH/0.6 M KHCO\(_3\). Cyclic AMP concentration was determined by RIA (25). The intracellular cAMP accumulation of the mutants was calculated as percentage of DMSO-treated WT receptor using the formula \[ \frac{\text{mutant}}{\text{WT}} \times 100\% \] for HEK293 cells or the formula \[ \frac{(\text{mutant} - \text{pcDNA3.1})}{(\text{WT} - \text{pcDNA3.1})} \times 100\% \] for Neuro2a and N1E-115 cells.

**DATA ANALYSIS**

Data were analyzed using GraphPad Prism 4.0 software (San Diego, CA, USA). The statistical significance of the differences between DMSO and Ipsen 5i treated cells was assessed by Student’s \(t\)-test.

**RESULTS**

**Ipsen 5i rescued the cell surface expression of mutant MC4Rs**

To investigate whether Ipsen 5i acted as a pharmacoperone rescuing the cell surface expression of mutant MC4Rs, we studied 11 mutants (S58C, N62S, I69R, P78L, C84R, G98R, Y157S, W174C, P260Q, F261S, and C271Y) that have reduced or absent cell surface expression (16, 28, 30) (Figure 1). We first visualized the cell...
FIGURE 3 | Ipsen 5i rescued the cell surface expression of intracellularly retained mutant MC4Rs in HEK293 cells as quantitated by flow cytometry. HEK293 cells stably expressing WT or mutant MC4Rs were treated with 10^{-5} M Ipsen 5i for 24 h and then stained with Alexa Fluor 488-conjugated antibody. The immunostaining was measured using a C6 Accuri Cytometer. The results are expressed as % DMSO-treated WT cell surface expression level after correction of the non-specific staining in cells expressing the empty vector. Results are shown as mean ± SEM of at least three independent experiments.

*Significantly different from the DMSO-treated control group, p < 0.05.

Neuro2a cells transiently expressing WT or mutant MC4Rs were treated with 10^{-5} M Ipsen 5i for 24 h and then were used for flow cytometry studies. S58C was not further studied in neuronal cells because as described later its function was not rescued by Ipsen 5i. As shown in Figure 4, the cell surface expression of eight mutants (N62S, I69R, P78L, C84R, G98R, W174C, P260Q, and C271Y) was increased with Ipsen 5i treatment compared with the DMSO-treated control group. The cell surface expression of I69R was slightly (although significantly) increased in Neuro2a cells whereas it was not increased in HEK293 cells. The increase of cell surface expression of F261S was not statistically significant in Neuro2a cells. One mutant (Y157S) that was rescued by Ipsen 5i in HEK293 cells was not rescued in Neuro2a cells.

THE MAJORITY OF THE MUTANT MC4Rs RESCUED WITH Ipsen 5i COULD RESPOND TO AGONIST STIMULATION WITH INCREASED cAMP GENERATION

We next investigated whether Ipsen 5i-rescued mutant MC4Rs were functional in generating cAMP at the cell surface. HEK293 cells stably expressing WT or mutant MC4Rs were incubated with different concentrations of Ipsen 5i for 24 h, and then stimulated with 10^{-6} M NDP-MSH. The intracellular cAMP accumulation was measured. As shown in Figure 5, the cAMP accumulation of WT MC4R was decreased by approximately 30% with 10^{-6} M Ipsen 5i treatment and by 80% with 10^{-5} M Ipsen 5i treatment. We observed an increase in cAMP accumulation at 10^{-9} M Ipsen 5i for C84R and W174C and a maximal increase at a concentration between 10^{-8} and 10^{-6} M for N62S, P78L, C84R, Y157S, W174C, P260Q, and C271Y. Unlike most of the mutants that decreased cAMP accumulation at 10^{-5} M Ipsen 5i, I69R had a maximal cAMP accumulation at that concentration. The signaling of S58C and G98R was not increased by Ipsen 5i.

In Neuro2a cells transiently expressing MC4Rs, we also observed an increase in cAMP accumulation at 10^{-9} M Ipsen 5i and a maximal increase at 10^{-6} M Ipsen 5i (or at 10^{-5} M Ipsen 5i for I69R) in Neuro2a cells (Figure 6A). As shown in Figure 6B, with 10^{-6} M Ipsen 5i treatment in Neuro2a cells, seven mutants...
FIGURE 5 | Ipsen 5i rescued the function of intracellularly retained mutant MC4Rs in HEK293 cells. HEK293 cells stably expressing WT or mutant MC4Rs were treated with either different concentrations of Ipsen 5i (A), 10^{-6} M Ipsen 5i (B), or DMSO as control for 24 h. Cells were washed twice and stimulated with 10^{-6} M NDP-MSH for 1 h. Intracellular cAMP samples were collected and cAMP concentrations were measured using RIA. The results are expressed as % DMSO-treated WT cAMP production. Data points are shown as mean ± SEM of at least two or three independent experiments. *Significantly different from the DMSO-treated control group, p < 0.05.

(N62S, I69R, P78L, C84R, W174C, P260Q, and C271Y) had significantly increased cAMP accumulation whereas signaling of three mutants (G98R, Y157S, and F261S) was not increased by Ipsen 5i. High concentration of Ipsen 5i did not decrease the cAMP accumulation of WT or mutant MC4Rs as dramatically as seen in HEK293 cells (Figure 6A). Our results obtained from N1E-115 cells were similar with those obtained from Neuro2a cells (Figure 7).

Ipsen 5i DID NOT AFFECT MUTANT MC4Rs THAT ARE EXPRESSED AT THE CELL SURFACE
To investigate whether Ipsen 5i rescued the function of mutant MC4Rs that are expressed at the cell surface but have other defects, we studied four mutants that are defective in ligand binding ([\Delta 88-92]) (32) (Class III according the classification proposed by Tao (33)), signaling (D90N and I102S) (29, 34) (Class IV), or with no obvious defect (N274S) (28) (Class V). As shown in Figures 6B and 7, 10^{-6} Ipsen 5i had no effect on the signaling of these four mutants.

SPECIFICITY OF THE MC4R MUTANT RESCUE
To investigate whether cell impermeable peptide ligands of the MC4R or cell permeable ligands of other receptors could rescue mutant MC4Rs, we studied the effect of two MC4R peptide agonists (NDP-MSH and \alpha-MSH), one MC4R peptide antagonist (SHU9119), and one pharmacoperone of \delta opioid receptor (nal-trexone) (35) (Figure 8A) on C84R MC4R. As shown in Figure 8B, NDP-MSH and \alpha-MSH decreased the signaling of WT MC4R by approximately 50%. However, none of the four ligands rescued the signaling of C84R MC4R.

To investigate whether Ipsen 5i specifically rescues mutant MC4Rs, we studied the effect of Ipsen 5i on one of intracellularly retained mutant MC3Rs (I335S) (27, 36). As shown in Figure 8C, Ipsen 5i had no effect on the cell surface expression or signaling of I335S MC3R.

DISCUSSION
Most of the inactivating mutations in GPCRs causing human diseases result from protein misfolding and subsequent retention and degradation by the ER quality control system (22). Misrouted receptors may retain intrinsic function and become functional when correctly located (37). Pharmacoperones that can permeate plasma membrane specifically stabilize the conformation and correct the trafficking of misfolded receptors, thus, rescuing the receptor and curing human diseases (38–41). In the current study, we identified Ipsen 5i, an antagonist of the MC4R, as a potent pharmacoperone specifically rescuing the cell surface expression and function of intracellularly retained mutant MC4Rs.

Our results showed that all 11 intracellularly retained mutants studied herein could be rescued to the cell surface by Ipsen 5i in at
Tao and Huang

**FIGURE 6** | Ipsen 5i rescued the function of intracellularly retained mutant MC4Rs in Neuro2a cells. Neuro2a cells transiently expressing WT or mutant MC4Rs were treated with either different concentrations of Ipsen 5i (A), 10^{-6} M Ipsen 5i (B), or DMSO as control. The results are expressed as % DMSO-treated WT cAMP production after correction of the cAMP production in cells expressing the empty vector. Data points are mean±SEM of at least three independent experiments. See the legend to Figure 5 for other details.

**FIGURE 7** | Ipsen 5i rescued the function of intracellularly retained mutant MC4Rs in N1E-115 cells. N1E-115 cells transiently expressing WT or mutant MC4Rs were treated with 10^{-6} M Ipsen 5i or DMSO as control. The results are expressed as % DMSO-treated WT cAMP production after correction of the cAMP production in cells expressing the empty vector. Results are shown as mean±SEM of at least three independent experiments. See the legend to Figure 5 for details.

least one cell line (Table 1). Y157S could be significantly rescued in HEK293 cells but not in neuronal cells whereas I69R was partially rescued in neuronal cells but not in HEK293 cells. The effects of Ipsen 5i on eight mutants were similar between HEK293 and neuronal cell lines. The cell surface expression of most mutants treated with Ipsen 5i was increased to at least 50% of or even similar to that of the DMSO-treated WT receptor. The rescuing efficacies of Ipsen 5i were different for different mutations. I69R was the most difficult to rescue because it could only be maximally rescued with the highest concentration of Ipsen 5i (10^{-5} M) and could not be rescued with another pharmacopore of the MC4R, ML00253764 (unpublished observations). This suggests that I69R induces a large change in the receptor conformation that is difficult to be stabilized.

Eight of the 11 mutants rescued to the cell surface were functional in cAMP production (N62S, I69R, P78L, C84R, Y157S, W174C, P260Q, and C271Y) in HEK293 cells and seven mutants, with the exception of Y157S, in neuronal cells (Table 1). These results suggest that these mutants, although misfolded and retained intracellularly, retain the ability to bind to agonist and initiate downstream signaling. Ipsen 5i treatment did not significantly increase F261S signaling. G98R, although rescued to the cell surface, did not respond to NDP-MSH stimulation with increased cAMP generation, suggesting that this mutant was also defective in ligand binding and/or signaling. We are also unable to rescue G98R functionally using a small molecule agonist as the pharmacopore (42). Despite low cell surface expression, S58C has significant signaling (28), likely due to the presence of spare receptor (33).
Ipsen 5i treatment significantly increased cell surface expression of S58C (Figures 2 and 3). However, its signaling was not increased and tended to decrease.

The signaling of WT MC4R was dramatically decreased when treated with $10^{-5}$ M Ipsen 5i in HEK293 cells (Figure 5). The residual Ipsen 5i that had not been washed away presumably still occupied the binding site of the MC4R and therefore, antagonized the stimulation of NDP-MSH. Although Ipsen 5i has a high-affinity with the MC4R ($K_i$, 2 nM), it has relatively low functional antagonist potency (77 nM) (24), minimizing its antagonizing effect on NDP-MSH. Indeed, in our study, $10^{-6}$ and $10^{-7}$ M Ipsen 5i, which already had significant pharmacopore rescuing ability, only decreased the signaling of WT MC4R by approximately 30 or 20% in HEK293 cells, respectively (Figure 5). Interestingly, we had not observed such dramatic decrease in WT MC4R signaling in neuronal cells (Figures 6 and 7), suggesting that it might be easier for Ipsen 5i to dissociate from the MC4R expressed in neuronal cells.

Ipsen 5i has low affinity for the MC3R ($K_i$, 400 nM) and therefore, we investigated whether Ipsen 5i could rescue misrouted MC3R mutant I335S. We found that Ipsen 5i did not increase the cell surface expression or function of I335S MC3R, suggesting that Ipsen 5i was a pharmacopere specific for the MC4R. Although Ipsen 5i was a potent pharmacopere of the MC4R, it had no effect on mutant MC4Rs defective in ligand binding or signaling, suggesting that Ipsen 5i could only rescue the function of the intracellularly retained mutant MC4Rs. As expected, cell impermeable peptide ligands of the MC4R did not rescue the function of misrouted mutant MC4R C84R whereas cell permeable Ipsen 5i did. Consistent with previous reports on several other...
| Mutants   | HEK293 cells | Neuronal cells |
|-----------|--------------|---------------|
|           | Function     | Function      |
| WT        | ↑            | −             |
| S58C      | ↑            | /             |
| N62S      | ↑            | ↑ ↑ ↑         |
| I69R      | −            | ↑ ↑ ↑         |
| P78L      | ↑ ↑          | ↑ ↑           |
| C84R      | ↑ ↑          | ↑ ↑           |
| G98R      | ↑ ↑ ↑        | ↑ ↑           |
| Y157S     | ↑ ↑          | −             |
| W174C     | ↑ ↓          | ↑ ↑           |
| P260Q     | ↑ ↑          | ↑ ↑           |
| F261S     | ↑            | −             |
| S58C      | ↑            | −             |
| C271Y     | ↑ ↓          | ↑ ↑           |

↑, increase; ↓, decrease; −, no significant effect; /, not studied herein.

GPCRs (35, 43–45), this observation suggests that only cell permeable small compound could act as a pharmacoperone and the rescuing action occurred intracellularly. Peptide ligands decreased the signaling of WT MC4R probably by inducing internalization and down-regulation (NDP-MSH and α-MSH) or by antagonizing NDP-MSH (SHU9119). Naltrexone, a pharmacoperone of δ opioid receptor (35), also did not correct the function of C84R MC4R, suggesting that only ligands for the MC4R could act as MC4R pharmacoperones.

In summary, Ipson 5i increased the cell surface expression of all 11 intracellularly retained mutant MC4Rs (100%) studied herein and eight of the 11 mutants (73%) were functional at the cell surface in at least one cell line. Ipson 5i could rescue mutant MC4Rs at a concentration as low as 10^−9 M. To our knowledge, it was the most potent pharmacoperone of the MC4R identified so far. Future experiments aimed at demonstrating the *in vivo* efficacy of this ligand in transgenic animals will represent another important step toward personalized medicine for treating patients harboring these MC4R mutations.

ACKNOWLEDGMENTS

This study was funded by American Diabetes Association grant 1-12-BS212, Auburn University Intramural Grant Program and Interdisciplinary Grant of College of Veterinary Medicine.

REFERENCES

1. Gantz I, Miwa H, Kondya Y, Shimoto Y, Tahiroh T, Watson SJ, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. *J Biol Chem* (1993) 268:15174–9.
2. Mountjoy RG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. *Mol Endocrinol* (1994) 8:1258–308. doi:10.1210/mend.8.10.7854347
3. Cone RD. Anatomy and regulation of the central melanocortin system. *Nat Neurosci* (2005) 8:571–8. doi:10.1038/nn1455
4. Hussels D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* (1997) 88:131–41. doi:10.1016/S0092-8674(00)81865-6
5. Balharsas N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. *Cell* (2005) 123:493–505. doi:10.1016/j.cell.2005.08.035
6. Rossi J, Balharsas N, Olson D, Scott M, Berghuld E, Lee CE, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. *Cell Metab* (2011) 13:195–204. doi:10.1016/j.cmet.2011.01.010
7. Hinney A, Schmidt A, Nottebohm K, Heibult O, Becker I, Ziegler A, et al. Severe mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. *J Clin Endocrinol Metab* (1999) 84:1483–6. doi:10.1210/jcem.84.4.5778
8. Vasse C, Clement K, Guy-Grand B, Frouguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. *Nat Genet* (1998) 20:13–4. doi:10.1038/2407
9. Yeo GS, Farooqui IS, Arminian S, Halasli DJ, Stanhope RG, O’Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. *Nat Genet* (1998) 20:111–2. doi:10.1038/2404
10. Farooqui IS, Keogh JM, Yeo GS, Lank EL, Chesterton T, O’Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med* (2003) 348:1085–95. doi:10.1056/NEJMoa020390
11. Hinney A, Volckmar AL, Knoll N. Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis. *Prog Mol Biol Transl Sci* (2013) 114:147–91. doi:10.1016/B978-0-12-386933-3.00005-4
12. Hohenadel MG, Thearle MS, Grice BA, Huang H, Dai MH, Tao YX, et al. Brain-derived neurotrophic factor in human subjects with function-altering melanocortin-4 receptor variants. *Int J Obes* (Lond) (2013). doi:10.1038/ijo.2013.221
13. Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysicsiology. *Endor Rev* (2010) 31:506–43. doi:10.1210/endo.2009-0037
14. Meimandou I, Gooljar SB, Ramnarace N, Anthonypillai L, Clark AJ, Chapple JP. The cytosolic chaperone Hsc70 promotes traffic to the cell surface of intracellular retained melanocortin-4 receptor mutants. *Mel Endocinol* (2011) 28:1650–60. doi:10.1210/me.2011-1020
15. Granell S, Mohammad S, Ramanagoudra-Bhejappa R, Baldini G. Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone. *Mel Endocinol* (2010) 24:1805–21. doi:10.1210/me.2010-0071
16. Fan ZG, Tao YX. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. *J Cell Mol Med* (2009) 13:2628–82. doi:10.1111/j.1582-4934.2009.00726.x
17. Rene P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HL, Farooqui IS, et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. *J Pharmacol Exp Ther* (2010) 335:520–32. doi:10.1124/pept.110.172098
18. Ward NA, Hurst S, Williams J, Findlay JB. Pharmacological chaperones increase the cell-surface expression of intracellularly retained mutants of the melanocortin 4 receptor with unique rescuing efficacy profiles. *Biochem Soc Trans* (2012) 40:717–20. doi:10.1042/BST20110764
19. Lester HA, Miwa JM, Srinivasan R. Psychiatric drugs bind to classical targets within early eucytotic pathways therapeutic efficaces. *Biol Psychiatry* (2012) 72:907–15. doi:10.1016/j.biopsych.2012.05.020
20. Loo TW, Clarke DM. Chemical and pharmacological chaperones as new therapeutic agents. *Expert Rev Mol Med* (2007) 9:i1–18. doi:10.1017/S146299407000361
21. Tao YX, Conn PM. Chaperoning G protein-coupled receptors: from cell biology to therapeutics. *Endor Rev* (2014) 35:686–721. doi:10.1210/endo.2013-1121
22. Tao YX. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. *Pharmacol Ther* (2006) 111:949–73. doi:10.1016/j.pharmthera.2006.02.088
23. Huang H, Tao YX. Pleiotropic functions of the transmembrane domain 6 of human melanocortin-4 receptor. *J Mol Endocinol* (2012) 49:237–48. doi:10.1530/JME-12-0161
24. Ponti L, Brault V, Sackur C, Bernertiere S, Camara J, Plas P, et al. Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor. *Bioorg Med Chem Lett* (2007) 17:4464–70. doi:10.1016/j.bmcl.2007.06.010
25. Tao YX, Huang H, Wang ZJ, Yang F, Williams JN, Nikiforovich GV. Constitutive activity of neural melanocortin receptors. *Methods Enzymlol* (2010) 484:267–79. doi:10.1016/B978-0-12-381298-8.00014-9
26. Mo XL, Tao YX. Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors. *Biochim Biophys Acta* (2013) **1832**:1939–48. doi:10.1016/j.bbadis.2013.06.006

27. Tao YX. Functional characterization of novel melanocortin-3 receptor mutations identified from obese subjects. *Biochim Biophys Acta* (2007) **1772**:1167–74. doi:10.1016/j.bbadis.2007.09.002

28. Tao YX, Segaloff DL. Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. *Endocrinology* (2003) **144**:4544–51. doi:10.1210/en.2003-0524

29. Tao YX, Segaloff DL. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. *J Clin Endocrinol Metab* (2005) **90**:5632–8. doi:10.1210/jc.2005-0519

30. Wang ZQ, Tao YX. Functional studies on twenty novel naturally occurring melanocortin-4 receptor mutations. *Biochim Biophys Acta* (2011) **1812**:1190–9. doi:10.1016/j.bbadis.2011.06.008

31. Wang SX, Fan ZC, Tao YX. Functions of acidic transmembrane residues in human melanocortin-3 receptor binding and activation. *Biochem Pharmacol* (2008) **76**:520–30. doi:10.1016/j.bcp.2008.05.026

32. Donohouse PA, Tao YX, Collins M, Yeo GH, O’Rahilly S, Segaloff DL. Deletion of codons 88–92 of the melanocortin-4 receptor gene: a novel deleterious mutation in an obese female. *J Clin Endocrinol Metab* (2003) **88**:5841–5. doi:10.1210/jc.2003-030903

33. Tao YX. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. *Mol Cell Endocrinol* (2005) **239**:1–14. doi:10.1016/j.mce.2005.04.012

34. Biebermann H, Krude H, Ehner A, Churbanov V, Gudermann T, Grutters A. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. *Diabetes* (2003) **52**:2984–8. doi:10.2337/diabetes.52.12.2984

35. Petaja-Repo UE, Hogge S, Bhalla S, Laperriere A, Morello JP, Bovier M. Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. *EMBO J* (2002) **21**:1628–37. doi:10.1093/emboj/21.7.1628

36. Mencarelli M, Dubern B, Alli R, Maestrini S, Benajiba L, Tagliaferri M, et al. Rare melanocortin-3 receptor mutations with in vitro functional consequences are associated with human obesity. *Hum Mol Genet* (2011) **20**:392–9. doi:10.1093/hmg/ddq472

37. Conn PM, Ulloa-Aguirre A. Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. *Adv Pharmacol* (2011) **62**:109–41. doi:10.1016/B978-0-12-385952-5.00008-7

38. Conn PM, Ulloa-Aguirre A, Ito J, Janovick JA. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. *Pharmacol Rev* (2007) **59**:225–50. doi:10.1124/pr.59.3.2

39. Huang Y, Breitwieser GE. Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis. *J Biol Chem* (2007) **282**:9517–25. doi:10.1074/jbc.M609045200

40. Maya-Nunez G, Ulloa-Aguirre A, Janovick JA, Conn PM. Pharmacological chaperones correct misfolded GPCRs and rescue function: protein trafficking as a therapeutic target. *Subcell Biochem* (2012) **63**:263–89. doi:10.1007/978-94-007-4765-4_14

41. Newton CL, Whay AM, Mc Ardle CA, Zhang M, van Koppen CJ, de la Lagemaat R, et al. Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist. *Proc Natl Acad Sci U S A* (2011) **108**:7172–6. doi:10.1073/pnas.1015723108

42. Huang H, Tao YX. A small molecule agonist THIQ as a novel pharmacop- one for intracellularly retained melanocortin-4 receptor mutants. *Int J Biol Sci* (2014) **10**:817–24. doi:10.7150/ijbs.9625

43. Bernier V, Lagace M, Lonergan M, Arthus MF, Bichet DG, Bouvier M. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49659. *Mol Endocrinol* (2004) **18**:2074–84. doi:10.1210/me.2004-0080

44. Janovick JA, Maya-Nunez G, Conn PM. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misfolded proteins as a novel disease etiology and therapeutic target. *J Clin Endocrinol Metab* (2002) **87**:3255–62. doi:10.1210/jcem.87.7.8582

45. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. *J Clin Invest* (2000) **105**:887–95. doi:10.1172/JCI8688

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 08 May 2014; accepted: 20 July 2014; published online: 04 August 2014.

**Citation:** Tao Y-X and Huang H (2014) Ipsen 5i is a novel potent pharmacop- one for intracellularly retained melanocortin-4 receptor mutants. *Front Endocrinol* **5**:131. doi: 10.3389/fendo.2014.00131

This article was submitted to Pituitary Endocrinology, a section of the journal *Frontiers in Endocrinology*. Copyright © 2014 Tao and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.